Trials / Completed
CompletedNCT05493826
Real World Study on the Use of Cemiplimab in Adult Patients in UK
Real-world Evidence Study on the Early Use of Cemiplimab in the UK: REACT-CEMI (Real World Evidence of Advanced CSCC Treatment - With CEMIplimab)
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 110 (actual)
- Sponsor
- Sanofi · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The primary objective is to describe the real-world clinical effectiveness of cemiplimab in patients with locally advanced cutaneous squamous cell carcinoma (laCSCC) or metastatic cutaneous squamous cell carcinoma (mCSCC) treated in routine clinical practice.
Detailed description
Patients initiating treatment with cemiplimab in the UK between 2nd July 2019 and 30th November 2020, will be followed for a minimum of 12 and a maximum of 36 months from initiation of cemiplimab.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| OTHER | No intervention | Non-interventional study based on secondary use of hospital medical record |
Timeline
- Start date
- 2022-07-18
- Primary completion
- 2022-11-01
- Completion
- 2022-11-01
- First posted
- 2022-08-09
- Last updated
- 2023-07-14
Locations
1 site across 1 country: United Kingdom
Source: ClinicalTrials.gov record NCT05493826. Inclusion in this directory is not an endorsement.